Federal Circuit Denies En Banc Review of Norvasc Decision

The pharmaceutical and biotech industries were dealt a blow when the Federal Circuit U.S. Court of Appeals decided not to reconsider its ruling that Pfizer's Norvasc (amlodipine besylate) patent is obvious